Publication: Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children
Issued Date
2020-05-01
Resource Type
ISSN
15326535
00099236
00099236
DOI
Other identifier(s)
2-s2.0-85077901504
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Pharmacology and Therapeutics. Vol.107, No.5 (2020), 1179-1188
Suggested Citation
Junjie Ding, Matthew E. Coldiron, Bachir Assao, Ousmane Guindo, Daniel Blessborn, Markus Winterberg, Rebecca F. Grais, Alena Koscalova, Celine Langendorf, Joel Tarning Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children. Clinical Pharmacology and Therapeutics. Vol.107, No.5 (2020), 1179-1188. doi:10.1002/cpt.1707 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/54597
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children
Abstract
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC. Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case-control study to evaluate SMC effectiveness (n = 869). Amodiaquine and desethylamodiaquine concentration-time profiles were described simultaneously by two-compartment and three-compartment disposition models, respectively. The developed methodology to evaluate adherence showed a sensitivity of 65–71% when the first dose of SMC was directly observed and 71–73% when no doses were observed in a routine programmatic setting. Adherence simulations and measured desethylamodiaquine concentrations in the case-control children showed complete adherence (all doses taken) in < 20% of children. This result suggests that more efforts are needed urgently to improve the adherence to SMC among children in this area.